Literature DB >> 6541344

Muscarinic and nicotinic effects on yawning and tongue protruding in the rat.

I Ushijima, K Yamada, T Inoue, T Tokunaga, T Furukawa, Y Noda.   

Abstract

Physostigmine, an anticholinesterase agent, elicited yawning with a marked protrusion of the tongue and teeth chattering. Yawning and chattering were also observed after pilocarpine, a cholinergic agonist predominantly acting upon muscarinic receptors. Apomorphine at low doses (0.1-0.5 mg/kg), which preferentially activates presynaptic dopamine autoreceptors, elicited yawning, whereas at high doses (1-2 mg/kg) it produced stereotypy. Yawning induced by both cholinergic agonists and apomorphine was inhibited by scopolamine, a muscarinic receptor blocking agent, but not by methylscopolamine, a peripheral anticholinergic agent and mecamylamine, a nicotinic receptor blocking agent. Low dose (0.02 mg/kg) of haloperidol, which has been reported to block presynaptic dopamine autoreceptors, inhibited apomorphine-induced yawning but did not affect cholinergic agonist-induced yawning. Physostigmine-elicited tongue protruding was inhibited by mecamylamine. The results imply that yawning behavior is essentially associated with the stimulation of central muscarinic receptors, and that physostigmine also induces tongue protruding by activating the central nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541344     DOI: 10.1016/0091-3057(84)90229-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  17 in total

1.  On yawning and its functions.

Authors:  R Baenninger
Journal:  Psychon Bull Rev       Date:  1997-06

2.  Occurrence of yawning and decrease of prolactin levels via stimulation of dopamine D2-receptors after administration of SND 919 in rats.

Authors:  S Matsumoto; K Yamada; M Nagashima; M Domae; K Shirakawa; T Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

3.  Involvement of central beta-adrenoceptors in the regulation of yawning responses.

Authors:  K Yamada; S Matsumoto; M Nagashima; M Kumagai; H Kimura; T Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

4.  The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation.

Authors:  A J Stoessl; C T Dourish; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat.

Authors:  J D Salamone; M D Lalies; S L Channell; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

7.  Yawning induced by apomorphine, physostigmine or pilocarpine is potentiated by dihydropyridine calcium channel blockers.

Authors:  A Bourson; P C Moser
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Effects of adenosine agents on apomorphine-induced yawning in rats.

Authors:  M R Zarrindast; F Fatehi; M Mohagheghi-Badi
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

9.  Oro-facial dyskinesia and the sub-commissural part of the globus pallidus in the cat: role of acetylcholine and its interaction with GABA.

Authors:  W P Spooren; E Cuypers; A R Cools
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.

Authors:  M R Zarrindast; M Poursoltan
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.